Research Funding

  • July 2, 2013 - May 31, 2018 - Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA173085
  • March 1, 1982 - May 31, 2015 - Bio-Organic Biomedical Mass Spectrometry Resource, Co-Investigator. Sponsor: NIH, Sponsor Award ID: P41RR001614
  • July 1, 2005 - August 31, 2010 - In Vivo Analysis of Oncogenic Kras in Leukemogenesis, Principal Investigator. Sponsor: NIH, Sponsor Award ID: K08CA103868
  • July 2, 2013 - May 31, 2018 - Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA173085

Education

Princeton University, A.B., 1990, Molecular Biology
University of California, Los Angeles, Ph.D., 1998, Molecular Biology
University of California, Los Angeles, M.D., 1998, Medicine
University of California, San Francisco, Resident, 1998-2000, Pediatrics
University of California, San Francisco, Fellow, 2000-2003, Hematology/Oncology

Honors & Awards

  • 1990
    Cum Laude, Princeton University
  • 1990
    Phi Beta Kappa
  • 1990
    Medical Scientist Training Program Fellowship, University of California, Los Angeles
  • 2000-2003
    Campini Fellowship, University of California, San Francisco
  • 2004
    David G. Nathan Award, Society for Pediatric Research
  • 2004
    Melvin Grumbach Pediatric Research Award, UCSF
  • 2005
    Basic Research Scholar American Society of Hematology
  • 2010
    Fellows' Leadership and Advocacy Group FacultyLeadership Award, Department of Pediatrics, UCSF

Selected Publications

  1. Morales CE, Stieglitz E, Kogan SC, Loh ML, Braun BS. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Adv. 2021 Aug 31.  View on PubMed
  2. Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021 Aug 01; 106(8):2242-2245.  View on PubMed
  3. Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI Insight. 2020 11 05; 5(21).  View on PubMed
  4. Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv. 2019 11 26; 3(22):3575-3578.  View on PubMed
  5. Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020 02; 34(2):662-666.  View on PubMed
  6. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRASA146T. Cancer Discov. 2019 06; 9(6):738-755.  View on PubMed
  7. Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML. Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. Cancer Res. 2019 05 01; 79(9):2339-2351.  View on PubMed
  8. Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017 12 19; 8(1):2127.  View on PubMed
  9. Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res. 2017 11 01; 77(21):5706-5711.  View on PubMed
  10. Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia. 2016 06; 30(6):1335-43.  View on PubMed
  11. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2016 Jan; 126(1):404.  View on PubMed
  12. Braun BS. Traxtile: Interactive editing of cell tracks in time-lapse images. Biotechniques. 2015 Aug; 59(2):82-6.  View on PubMed
  13. Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015 Jan 15; 125(3):516-24.  View on PubMed
  14. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 03; 6(304):ra105.  View on PubMed
  15. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan; 123(1):335-9.  View on PubMed
  16. Braun BS. KIT's ship comes in. Blood. 2012 Sep 27; 120(13):2541-2.  View on PubMed
  17. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012 Oct 25; 120(17):3397-406.  View on PubMed
  18. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011 Mar 30; 3(76):76ra27.  View on PubMed
  19. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011 Apr 21; 117(16):4253-61.  View on PubMed
  20. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011 Feb 10; 117(6):2022-32.  View on PubMed

Go to UCSF Profiles, powered by CTSI